[Source: Science Daily]
A new study in children aged 6 to 12 years of dasotraline, a promising new treatment for attention deficit hyperactivity disorder (ADHD), showed significant improvement in efficacy in the treatment of ADHD compared to placebo beginning at week 1 and continuing throughout the study.
Robert Goldman, PhD, Sunovion Pharmaceuticals (Marlborough, MA and Fort Lee, NJ), and colleagues from Kennedy Krieger Institute/Johns Hopkins University (Baltimore, MD), New York University Langone Medical Center (New York, NY), and Massachusetts General Hospital (Boston, MA) coauthored the article entitled “Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial.”
Read the Rest of this Article on Science Daily